Comparison of Heart Rate Variability Analysis Durations and Their Relationship With Blood Pressure (HRV-BP)

Comparison of Heart Rate Variability Analysis Durations and Their Relationship With Blood Pressure: A Methodological Comparative Study

This observational study aims to compare heart rate variability (HRV) parameters obtained from different analysis durations in healthy adults and to examine how these parameters relate to resting blood pressure values. HRV is a noninvasive measure commonly used to assess autonomic nervous system activity. Standard short-term HRV analysis is typically based on 5-minute recordings, but shorter and longer analysis durations are also used in research and practice. This study will evaluate whether HRV values derived from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows differ from one another and whether their relationships with systolic blood pressure, diastolic blood pressure, and mean arterial pressure change according to analysis duration. Participants will attend a single study visit. After a rest period, resting blood pressure and pulse will be measured, and a continuous HRV recording will be obtained using a chest strap device. The study is designed to provide methodological information on the comparability of different HRV analysis durations under the same physiological conditions.

Study Overview

• Status: Not yet recruiting
• Conditions: Heart Rate Variability
• Intervention / Treatment: Other: Heart Rate Variability and Blood Pressure Assessment

Detailed Description

Heart rate variability (HRV) is widely used as a noninvasive indicator of autonomic nervous system regulation and provides information about sympathetic-parasympathetic balance. Although 5-minute recordings are commonly recommended for short-term HRV assessment, interest has increased in ultra-short and longer analysis durations because they may improve feasibility and reduce participant burden. However, the extent to which HRV parameters derived from different analysis durations agree with one another remains uncertain, particularly when comparing time-domain and frequency-domain measures. In addition, limited research has systematically examined whether the relationship between HRV and blood pressure varies according to HRV analysis duration. This study is intended to address that methodological gap.

This is a single-center, single-visit, observational methodological comparison study in healthy adults. Eligible participants will complete a sociodemographic data form and will undergo resting hemodynamic assessment and HRV recording under standardized conditions. Measurements will be performed in a quiet environment after an adaptation period. Resting systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric upper-arm blood pressure monitor. RR interval data will then be recorded continuously using the Polar H10 chest strap and analyzed using Kubios HRV software.

HRV analyses will be derived from a single continuous recording using predefined analysis windows of 1 minute, 5 minutes, 10 minutes, and 20 minutes. These windows will be extracted from the same physiological recording in order to minimize time-related variation and allow direct comparison across durations. Time-domain and frequency-domain HRV parameters will be calculated, and the agreement and comparability of measurements across analysis durations will be evaluated. Associations between HRV parameters and resting hemodynamic variables, including systolic blood pressure, diastolic blood pressure, mean arterial pressure, and pulse, will also be examined according to analysis duration.

The study is expected to provide methodological evidence regarding whether shorter or longer HRV analysis durations can be interpreted consistently relative to standard short-term recordings. The findings may help improve protocol standardization and support more accurate physiological and clinical interpretation of HRV data obtained under resting conditions.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Sefa Haktan Hatık, PhD; Phone Number: +90 368 271 55 28; Email: haktanhtk@gmail.com

Study Locations

• Turkey (Türkiye)
  • Artvin, Turkey (Türkiye)
    • Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory, Artvin,
    • Contact: Ömer Dicle Kızıl, MSc; Phone Number: +90 541 523 36 91; Email: omerdiclekizil@gmail.com
    • Sub-Investigator: Ömer Dicle Kızıl, MSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy adults aged 18 to 40 years
• Willing and able to provide informed consent
• Able to comply with pre-assessment instructions, including restrictions related to caffeine intake and strenuous physical activity
• No condition preventing heart rate variability and blood pressure measurements

Exclusion Criteria:

• History of diagnosed cardiovascular, neurological, or autonomic nervous system disease
• Known arrhythmia or pacemaker use
• Regular use of medications that may affect heart rate variability, such as beta blockers or antiarrhythmic drugs
• Acute infection, fever, or any condition affecting general health status on the day of assessment
• Severe motion artifact during measurement or technically unusable recordings

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Healthy Adult Assessment Group; Healthy adult participants will attend a single study visit and undergo resting hemodynamic and heart rate variability (HRV) assessment under standardized conditions. After an adaptation period, systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric blood pressure monitor. A continuous RR interval recording will then be obtained using the Polar H10 chest strap. HRV parameters will be derived from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same recording for methodological comparison.

Other: Heart Rate Variability and Blood Pressure Assessment; Participants will complete a single-visit resting physiological assessment under standardized conditions. After an adaptation period, systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric upper-arm blood pressure monitor. Continuous RR interval data will then be recorded using the Polar H10 chest strap and analyzed with Kubios HRV software. Heart rate variability parameters will be calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous recording for methodological comparison.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RMSSD Across Different Analysis Durations	Root mean square of successive differences (RMSSD), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.	Baseline, during a single study visit
SDNN Across Different Analysis Durations	Standard deviation of normal-to-normal intervals (SDNN), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.	Baseline, during a single study visit
Low-Frequency Power Across Different Analysis Durations	Low-frequency (LF) power, in ms^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.	Baseline, during a single study visit
High-Frequency Power Across Different Analysis Durations	High-frequency (HF) power, in ms^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.	Baseline, during a single study visit.
LF/HF Ratio Across Different Analysis Durations	Low-frequency/high-frequency (LF/HF) ratio calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.	Baseline, during a single study visit.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement of RMSSD Across Different Analysis Durations	Agreement of RMSSD values, in milliseconds (ms), obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.	Baseline, during a single study visit
Agreement of SDNN Across Different Analysis Durations	Agreement of SDNN values, in milliseconds (ms), obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.	Baseline, during a single study visit
Agreement of Low-Frequency Power Across Different Analysis Durations	Agreement of low-frequency (LF) power values, in ms^2, obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.	Baseline, during a single study visit
Agreement of High-Frequency Power Across Different Analysis Durations	Agreement of high-frequency (HF) power values, in ms^2, obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.	Baseline, during a single study visit
Agreement of LF/HF Ratio Across Different Analysis Durations	Agreement of low-frequency/high-frequency (LF/HF) ratio values obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.	Baseline, during a single study visit
Correlation Between RMSSD and Resting Systolic Blood Pressure	Correlation between RMSSD, in milliseconds (ms), and resting systolic blood pressure, in mmHg, measured under standardized resting conditions during the same study visit.	Baseline, during a single study visit
Correlation Between RMSSD and Resting Diastolic Blood Pressure	Correlation between RMSSD, in milliseconds (ms), and resting diastolic blood pressure, in mmHg, measured under standardized resting conditions during the same study visit.	Baseline, during a single study visit
Correlation Between RMSSD and Mean Arterial Pressure	Correlation between RMSSD, in milliseconds (ms), and mean arterial pressure, in mmHg, calculated from resting blood pressure measurements obtained during the same study visit.	Baseline, during a single study visit
Resting Systolic Blood Pressure	Resting systolic blood pressure, in mmHg, measured under standardized resting conditions before HRV recording.	Baseline, during a single study visit
Resting Diastolic Blood Pressure	Resting diastolic blood pressure, in mmHg, measured under standardized resting conditions before HRV recording.	Baseline, during a single study visit
Mean Arterial Pressure	Mean arterial pressure, in mmHg, calculated from resting systolic and diastolic blood pressure measurements obtained under standardized resting conditions before HRV recording.	Baseline, during a single study visit
Resting Pulse Rate	Resting pulse rate, in beats per minute, measured under standardized resting conditions before HRV recording.	Baseline, during a single study visit

Collaborators and Investigators

• Sponsor: Sinop University

Publications and helpful links

General Publications

• Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.
• Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017.
• Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010 May 28;141(2):122-31. doi: 10.1016/j.ijcard.2009.09.543. Epub 2009 Nov 11.
• Munoz ML, van Roon A, Riese H, Thio C, Oostenbroek E, Westrik I, de Geus EJ, Gansevoort R, Lefrandt J, Nolte IM, Snieder H. Validity of (Ultra-)Short Recordings for Heart Rate Variability Measurements. PLoS One. 2015 Sep 28;10(9):e0138921. doi: 10.1371/journal.pone.0138921. eCollection 2015.

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): September 15, 2026

Study Registration Dates

• First Submitted: April 6, 2026
• First Submitted That Met QC Criteria: April 13, 2026
• First Posted (Actual): April 15, 2026

Study Record Updates

• Last Update Posted (Actual): April 15, 2026
• Last Update Submitted That Met QC Criteria: April 13, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Autonomic Nervous System; Heart Rate Variability; HRV
• Other Study ID Numbers: TAVNS7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No